No headlines found.
PRNewswire (Thu, 18-Dec 8:05 AM ET)
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Pulmatrix trades on the NASDAQ stock market under the symbol PULM.
As of February 11, 2026, PULM stock price declined to $2.38 with 5,976 million shares trading.
PULM has a market cap of $8.69 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PULM traded as high as $10.40 and as low as $1.55.
The top ETF exchange traded funds that PULM belongs to (by Net Assets): VXF, DFAC, DCOR, DFSU.
PULM has underperformed the market in the last year with a price return of -68.6% while the SPY ETF gained +15.6%. PULM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.7% and -8.7%, respectively, while the SPY returned +1.8% and -0.5%, respectively.
PULM support price is $2.31 and resistance is $2.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PULM shares will trade within this expected range on the day.
